# KTX-2001

Source: https://onco.cc/drugs/ktx-2001/  
OnCo record `ktx-2001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KTX-2001 is an experimental small molecule from K36 Therapeutics, in phase 1 trials for metastatic castration-resistant prostate cancer.

## Summary

KTX-2001 (KTX2001) is a small molecule (oral) from K36 Therapeutics. An oral, selective NSD2 inhibitor that blocks NSD2 methylation of histone H3 at lysine 36 (H3K36), tested alone and with the androgen receptor pathway inhibitor darolutamide. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in one study linked below. NCT07103018 (STRIKE-001) recruiting per v2 API. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: KTX2001
- Tags: pipeline; ctgov-ingest
- Code: KTX-2001
- Modality: Small molecule (oral)
- Mechanism: An oral, selective NSD2 inhibitor that blocks NSD2 methylation of histone H3 at lysine 36 (H3K36), tested alone and with the androgen receptor pathway inhibitor darolutamide.

## Sources

- K36 Therapeutics: k36tx.com: https://www.k36tx.com/
- K36 Therapeutics: k36tx.com: https://www.k36tx.com/the-ktx-2001-program
- K36 Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07103018
- ClinicalTrials.gov: trials of KTX-2001: https://clinicaltrials.gov/search?intr=KTX-2001

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- targets: [NSD2](https://onco.cc/targets/nsd2/)
- companies: [K36 Therapeutics](https://onco.cc/companies/k36-therapeutics/)
- trials: [A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)](https://onco.cc/trials/nct07103018/)

---
JSON: https://onco.cc/api/v1/entities/ktx-2001.json